| 2022 | beta-catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine-resistant breast cancer cells | 이경은; 조정민 | Article |
| 2004 | Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: preliminary results from an open-label, multicenter phase II study | 이경은 | Meeting Abstract |
| 2020 | Choosing Wisely: The Korean Perspective and Launch of the 'Right Decision in Cancer Care' Initiative | 이경은; 김규보 | Article |
| 2023 | Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) | 이경은 | Article |
| 2022 | Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group | 이경은 | Article |
| 2018 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) | 이경은 | Article |
| 2019 | Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma | 성순희; 문병인; 이경은; 임우성; 백남선; 권형주; 우주현; 김현구 | Article |
| 2020 | Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 | 이경은 | Article |
| 2016 | Inhibition of beta-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line | 이경은; 남은미 | Article |
| 2015 | Manipulation of beta-catenin pathway to overcome endocrine resistance in breast cancer. | 이순남; 성주명; 이경은; 문영철; 남은미 | Meeting Abstract |
| 2021 | Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 | 이경은 | Article |
| 2019 | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 이경은 | Article |
| 2020 | Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) | 이경은 | Article |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B) | 이경은 | Article |
| 2014 | Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer | 이순남; 성순희; 성주명; 이경은; 문영철; 남은미 | Article |
| 2020 | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) | 이경은 | Article |
| 2019 | Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial | 이경은 | Article |
